FABP2 and colorectal carcinoma: All together these studies support the possible use of human proteins, such as iFABP and CD14, bacterial markers of endotoxemia and metabolites such as LPS, secondary bile acids, and SCFAs as promising biomarkers to evaluate gut barrier damage and suggest dietary strategies and use of pre-and pro-biotics for CRC prevention and treatment.